Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569149 | 0.87 | SYK (0.47) | EGFRSYKCSF1RKCNJ11CNR1 | |
| SCHEMBL15569787 | 0.86 | SYK (0.51) | EGFRSYKCSF1RKMT2A | |
| SCHEMBL15798219 | 0.86 | SYK (0.51) | EGFRSYKCSF1RKMT2A | |
| SCHEMBL15569778 | 0.86 | SYK (0.48) | SYKS1PR3CSF1RKCNJ11ROCK2 | |
| SCHEMBL15569576 | 0.80 | CYP2A6 (0.40) | SYKCSF1RKCNJ11ROCK2KMT2A | |
| SCHEMBL15569693 | 0.80 | ROCK2 (0.40) | SYKCSF1RROCK2KMT2AKDM4E | |
| SCHEMBL15569443 | 0.79 | MDM2 (0.44) | CNR1MDM2MAP4K4ROCK2CA12 | |
| SCHEMBL15569968 | 0.79 | CSF1R (0.51) | SYKCSF1RKCNJ11ROCK2KMT2A | |
| SCHEMBL15569806 | 0.77 | L3MBTL1 (0.47) | SYKCSF1RROCK2 | |
| SCHEMBL15569890 | 0.76 | EGFR (0.37) | EGFRSYKCSF1RKCNJ11MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458106-B2 | Phenyl-pyridine/pyrazine amides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458106-B2 | Phenyl-pyridine/pyrazine amides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2888232-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014029726-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | TP53, RB1, HCCS | EGFR 73/4885SYK 3149/4885S1PR1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.